gutflix
GI learning, personalised

Summary

REAL-WORLD EFFICACY AND SAFETY OF FILGOTINIB IN ULCERATIVE COLITIS: RESULTS FROM THE ENEIDA REGISTRY

ANA ROYO ESTEBAN

UEG Week Berlin 2025 Poster

IBD

October 6, 2025

A Spanish multicenter real-world study of 100 patients with moderate-to-severe ulcerative colitis treated with filgotinib showed steroid-free clinical remission rates of 43% at 12 weeks and 32% at 52 weeks, with a generally well-tolerated safety profile.

KEY POINTS

- In this retrospective observational study of 100 patients from 32 Spanish IBD units (2021-2024), steroid-free clinical remission was achieved in 43% at week 12 and 32% at week 52, with median treatment duration of 7 months and 62% persistence.
- The study population was heavily pre-treated, with 81% having prior anti-TNF exposure, 42% vedolizumab, 34% ustekinumab, and 18% prior JAK inhibitors; 88% had Mayo 2 or 3 endoscopic scores at baseline.
- Among patients previously exposed to JAK inhibitors, steroid-free clinical remission rates were lower at 33% at week 12 and 14% at week 52.
- Adverse events occurred in 17% of patients, with 18% of these considered serious; herpes zoster infection occurred in 2% (both vaccinated), with no cardiovascular or thromboembolic events reported.
- This real-world evidence may be relevant to gastroenterologists managing moderate-to-severe ulcerative colitis patients with extensive prior biologic exposure.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/307f6bdc-a813-11f0-8c01-0242ac140006

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.